NexCalibur Therapeutics is a pre-clinical stage biotechnology company that focuses on developing an innovative platform to design and produce personalised therapies and preventative vaccines for solid tumor cancers. 

Our personalised therapies are designed based on neoantigens, which are unique peptides from cancer cells that can trigger strong and specific immune responses against tumors while avoiding damage to healthy tissues. 

Our NexNeo platform uses a unique combination of artificial intelligence (AI) and engineered antigen-presenting cells to speed up the identification and validation of neoantigens, producing a cocktail of multiple neoantigens tailored for each patient. 

NexNeo platform is currently on a hybrid phase I/II clinical trial focusing on metastatic colorectal cancer patients.

Our NexNeo platform can also be used to design preventive cancer vaccine for healthy individuals with high risk of developing cancer (ie. family history or early signs of malignancy).

We conducted a large-scale screening for “public neoantigens” (ie. neoantigens commonly found in multiple individuals), which together could be formulated into “off-the-shelf” preventive vaccines.

This approach of early intervention could potentially save lives at a much lower cost, especially in high-risk individuals.

NexCalibur Therapeutics

Org chart

Teams

Offices